First biosimilar drug set to enter US market

Heidi Ledford

Nature, 2015, vol. 517, issue 7534, 253-254

Abstract: But such cheaper, generic versions of biological drugs face scientific, regulatory and patent hurdles.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/517253a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:517:y:2015:i:7534:d:10.1038_517253a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/517253a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().